Factor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes

BACKGROUND: Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is an effective oral antidiabetic agent as both monotherapy and when combined with insulin. Data from three observational studies performed in patients with type 2 diabetes receiving sitagliptin therapy in the routine clinical setting were...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Clin Med Res
Main Authors: Yuasa, Shouhei, Sato, Kazuyoshi, Takai, Masahiko, Ishikawa, Masashi, Umezawa, Shinichi, Kubota, Akira, Maeda, Hajime, Kanamori, Akira, Miyakawa, Masaaki, Tanaka, Yasushi, Terauchi, Yasuo, Matsuba, Ikuro
פורמט: Artigo
שפה:Inglês
יצא לאור: Elmer Press 2016
נושאים:
Original Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4852779/
https://ncbi.nlm.nih.gov/pubmed/27222674
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jocmr2540w
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים